Related Experiment Video
Updated: Oct 10, 2026

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets
Published on: May 11, 2015
Portopulmonary hypertension: an integrated approach to diagnosis, risk stratification, and management
Jesús Donate1, Susana Del Prado2, Andrés Tenes3
1Gastroenterology and Hepatology Department, Hospital Universitario Ramón y Cajal, IRYCIS, CIBERehd, Universidad de Alcalá, Madrid, Spain.
Abstract:
Portopulmonary hypertension (PoPH) is a complex and underrecognized form of pulmonary arterial hypertension arising in the setting of portal hypertension, in which outcomes are driven by the interplay between pulmonary vascular disease and liver dysfunction. Despite advances in hemodynamic definitions and targeted therapies, PoPH remains associated with significant morbidity and mortality, largely due to delayed diagnosis, challenges in risk stratification, and the absence of disease-specific management strategies. Recent insights support a paradigm shift from a purely hemodynamic view toward an integrated model encompassing pulmonary vascular load, right ventricular adaptation and hepatic reserve. This multidimensional framework has important implications for screening, prognostic assessment and therapeutic decision-making, particularly in the context of liver transplantation, where treatment is increasingly aimed at achieving transplant eligibility. In this review, we provide a comprehensive and clinically oriented overview of PoPH, integrating current evidence on pathophysiology, diagnosis, risk stratification and management. We highlight key limitations of existing approaches, discuss emerging therapeutic strategies and propose a conceptual framework to guide clinical practice and future research in this challenging condition.
Related Concept Videos
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue, improving...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Pulmonary Embolism I: Introduction
Pulmonary Embolism I: Introduction